微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 31.61% | -7.45% | -3.13% | 78/159 | 48.56% | 首药控股 | 96.95% | 行业排名> |
| 2026-06-30 | 32.63% | -13.53% | -1.87% | 107/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 33.25% | -8.4% | -10.25% | 104/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 37.05% | 5.24% | 8.49% | 100/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 34.15% | -5.4% | -9.5% | 106/159 | -2.12% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 37.73% | -0.06% | 3.96% | 98/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 36.3% | -13.66% | 3.11% | 100/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 35.2% | -17.6% | -2.48% | 109/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 36.1% | -17.65% | -4.39% | 104/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 37.75% | -10.47% | -10.19% | 102/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 42.04% | 0.9% | -1.6% | 90/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 42.72% | -1.27% | -2.54% | 100/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 43.84% | -1.6% | 3.95% | 94/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 42.17% | -6.91% | 1.22% | 98/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 41.67% | -15.2% | -3.71% | 95/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 43.27% | -14.45% | -2.86% | 95/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 44.55% | -10.67% | -1.67% | 87/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 45.3% | -9.13% | -7.79% | 87/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 49.13% | -4.3% | -2.87% | 79/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 50.58% | 18.02% | 1.43% | 81/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 49.87% | 9.12% | 0.02% | 73/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 49.86% | 2.73% | -2.89% | 79/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 51.34% | -1.69% | 19.8% | 70/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 42.86% | -24.32% | -6.23% | 98/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 45.7% | -20.72% | -5.83% | 80/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 48.53% | -17.27% | -7.07% | 74/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 52.22% | -7.87% | -7.78% | 58/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 56.63% | -1.71% | -1.76% | 66/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 57.64% | -0.2% | -1.74% | 52/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 58.66% | 2.39% | 3.49% | 54/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 56.69% | -1.76% | -1.62% | 49/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 57.62% | 7.81% | -0.24% | 59/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 57.76% | 8.18% | 0.81% | 46/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 57.29% | 12.19% | -0.7% | 48/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 57.7% | 12.85% | 7.97% | 42/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 53.44% | 19.26% | 0.1% | 56/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 53.39% | 27.51% | 4.54% | 42/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 51.07% | 25.29% | -0.11% | 43/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 51.13% | 29.09% | 14.1% | 37/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 44.81% | -0.16% | 7.02% | 57/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 41.87% | -5.3% | 2.73% | 42/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 40.76% | -16.82% | 2.91% | 50/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 39.61% | -14.41% | -11.75% | 42/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |